-
Cell Death Differ: Abnormal expression of SPAP5 promotes the proliferation of breast cancer cells
Time of Update: 2020-12-15
that YAP signals and SPAG5 are independent prognostic factors for disease-specific survival in breast cancer patients, the researchers found that SPAG5 was a direct target for miR-10b-3p.
relevant model diagram is interesting: in breast cancer patients, the high expression of SPAG5 is accompanied by the activation of the YAP/TAZ signal.
-
Scientists have discovered new cancer immunotherapy based on nanobiology
Time of Update: 2020-12-15
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
-
Complications and treatment of follow-up period after treatment in the abdominal aortic aneurysm cavity
Time of Update: 2020-12-15
follow-up time was 1 to 96 months, the overall mortality rate was 8.3%, the aneurysm-related mortality rate was 2.4%, the re-intervention rate was 3.7%, the main complications were leakage (with type II.
-
Adequate preoperative assessment is an early for successful surgery with co-operative abdominal aortic aneurysm
Time of Update: 2020-12-15
in clinical settings, clinicians routinely recommend coronary CTA or DSA testing in patients with abdominal aortic aneurysms; treatment of abdominal aortic aneurysms with combined coronary disease is generally an individualized selection strategy based on the patient's condition.
-
Bio-Thera submitted a marketing authorization application (MAA) for the Avastin biosimilar BAT1706 to the European Medicines Agency.
Time of Update: 2020-12-15
China's National Drug Administration (NMPA) is reviewing BAT1706's application for a biologics license to treat metastatic colorectal and non-small cell lung cancer.
Bio-Thera plans to submit THE BAT1706 BLA to the U.S. Food and Drug Administration (FDA) by the end of 2020.
-
JAMA: HFE p.C282Y men with pure co-children had a significantly increased risk of liver cancer
Time of Update: 2020-12-15
study found that male HFE p.C282Y pure co-carriers had a significantly increased risk of developing liver malignancies and death, compared to men, female pure-son carriers had a lower risk.
-
NEJM: Mother cell plasma cell-like degeneroma - case reported
Time of Update: 2020-12-15
patients received a 1-week course of treatment for dexamisong, and skin lesions were significantly reduced (figure B).
after 6 months of cure, the disease returned and the patient did not respond to further treatment.
-
Regent bioanty anti-Trap2 monoantial-Tub196 coupled agent JS108 completed the first patient drug
Time of Update: 2020-12-15
According to Mays Medical, Junshi Bio announced yesterday (November 25) that the first patient administration has been completed in Phase I clinical study (NCT04601285) of its products injected with recombinant humanized anti-Trap2 monoanti-Tub196 coupled agent (project code: JS108).
-
Neurology: Cancer rates and mortality rates in people with multiple sclerosis
Time of Update: 2020-12-15
In a recent study published in Neurology, an authoritative journal in the field of neurology, which aims to determine whether there is a difference in cancer risk in people with and without multiple sclerosis (MS), researchers used population-based data sources to compare morbidity and cancer-specific mortality in MS and matching populations.
-
Lancet Gastroen Hepatol: Postoperative celiac irrigation does not improve the survival of patients with stomach cancer
Time of Update: 2020-12-15
previous studies have shown that adequate celiac irrigation (EIPL) after surgery can reduce the risk of recurrence of the permission and improve patient survival.
1%), and 10 patients who died from adverse events, including 8 in the EIPL group.
-
Science Advances: Edwin Wang/Cui Qinghua/Li Jian and other teams have discovered the genetic code for human cancer
Time of Update: 2020-12-15
the study suggests that personalized guidance (precision prevention) on an individual's lifestyle/environment based on their cancer DNA fingerprint information can reduce the risk of cancer and thus play a preventive role.
, such as people carrying "external sensitivity-DNA fingerprints," avoiding smoking can reduce their risk of cancer.
-
Eur J Cancer: A new model for identifying stage I/IIA melanomas with a high risk of recurrence
Time of Update: 2020-12-15
580 patients with special queues had a prognosis for survival in patients with stage I/IIA melanoma, CP-GEP-identified high-risk patients (47%) had five-year RFS below the low-risk group (74% vs 89%; HR 2.98, 95% CI 1.78-4.98, p-lt;0.0001).
-
Cell Death Differ: Necrosis apoptosis is not necessary for the development of inflammatory or exudable colon cancer
Time of Update: 2020-12-15
the absence of MLKL or RIPK3 had no effect on the development of exudable colon cancer overall, these studies do not support the important role of necrosis apoptosis in gastrointestinal inflammation or cancer.
-
FDA approves Danyelza for bone or bone marrow recurrence or recurring neuroblastoma
Time of Update: 2020-12-15
danyelza can be used in combination with granulocyte macrophage collection stimulation factors (GM-CSF) in adult and child patients with bone or bone marrow recurrence or refrmmune high-risk neuroblastoma.
45 percent of the 22 patients treated in the study 201, 30 percent had DOR for six months or more, according to the FDA.
-
FDA approves DANYELZA (naxitamab-gqgk) for the treatment of neuroblastoma
Time of Update: 2020-12-15
Biopharmaceutical company Y-mAbs Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved DANYELZA (naxitamab-gqgk) in association with granulocyte macrophage cluster stimulation factor (GM-CSF) for the treatment of patients with bone recurrence or refractory high-risk neuroblastoma aged 1 year and older.
-
Nat Immunol: Inhibiting MEK reprograms CD8-T cells as tumor-resistant memory stem cells
Time of Update: 2020-12-15
After metabolic and lipid histological analysis of CD8 plus T cells treated by meki, they also observed that, unlike primitive cells, cells in the MEKi treatment group showed high proliferation capacity, higher expression of Sca1, and lower mitochondrial potential, in addition to higher memory and active markers.
-
Kingsley affiliate Legend has again released CAR-T clinical data with a total remission rate of 97 percent, and researchers expect to use it for more front-line treatments
Time of Update: 2020-12-15
Sidaki Oronse is a new class 1 drug used in the treatment of bio-products by Legendary Bios, a chime antigen-treated T-cell (CAR-T) therapy, and a number of clinical studies are currently under way to treat patients with relapsed or refractic multiple myeloma and more front-line patients, consisting of two single-domain antibodies targeting BCMA with a differentiated structure of CAR-T.
-
Cell Death Differ: Fra-2/AP-1 Lowers Fam212b expression to regulate the metastasis of melanoma cells
Time of Update: 2020-12-15
the expression of fra-2 in melanoma cell line can lead to increased lung and liver metastasis.
addition, over-expression of Fam212b enhances the β-catenin signaling pathline, while expression of Fam212b is also associated with increased metastasis of melanoma in patients and poor clinical prognosis.
-
NHS: Innovative cancer blood test that detects more than 50 types of cancer in advance
Time of Update: 2020-12-15
GRAIL pilot, which will begin in mid-2021, will involve 165,000 people: 140,000 of them are asymptomatic participants between the ages of 50 and 79, and another 25,000 are those experiencing possible cancer symptoms.
-
Leukemia: Dalatumantin anti-Calainadamine and dexamisong are treated with relapsed/incurable multiple myeloma
Time of Update: 2020-12-15
results showed that after 44.3 months of medium follow-up, D-Rd extended the progression-free lifetime (PFS) of the intended treatment population and patient subse group (middle 44.5 vs.
